These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238 [TBL] [Abstract][Full Text] [Related]
4. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223 [TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer]. Jin W; Wang LQ; Liu Y; Liu AJ Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020 [No Abstract] [Full Text] [Related]
6. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762 [TBL] [Abstract][Full Text] [Related]
7. Retained PAX2 expression associated with DNA mismatch repair deficiency in endometrial endometrioid adenocarcinoma. X Zhang G; Yang B Histopathology; 2024 Nov; 85(5):794-803. PubMed ID: 39075663 [TBL] [Abstract][Full Text] [Related]
8. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications. Hacking S; Jin C; Komforti M; Liang S; Nasim M Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening. Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272 [TBL] [Abstract][Full Text] [Related]
10. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers]. Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605 [No Abstract] [Full Text] [Related]
11. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Pasanen A; Loukovaara M; Bützow R Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377 [TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Expression in Endometrial Carcinoma. Zadeh SL; Duska LR; Mills AM Int J Gynecol Pathol; 2018 Mar; 37(2):167-173. PubMed ID: 28582344 [TBL] [Abstract][Full Text] [Related]
13. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions? Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610 [TBL] [Abstract][Full Text] [Related]
14. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors. Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699 [TBL] [Abstract][Full Text] [Related]
15. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. Köbel M; Tessier-Cloutier B; Leo J; Hoang LN; Gilks CB; Soslow RA; Delair D; Stewart CJR; Lee CH Int J Gynecol Pathol; 2017 Nov; 36(6):555-561. PubMed ID: 28114191 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. Hou Y; Nitta H; Parwani AV; Li Z Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926 [TBL] [Abstract][Full Text] [Related]
17. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Djordjevic B; Barkoh BA; Luthra R; Broaddus RR Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264 [TBL] [Abstract][Full Text] [Related]
19. Predicting Mismatch Repair Deficiency Status in Endometrial Cancer through Multi-Resolution Ensemble Learning in Digital Pathology. Whangbo J; Lee YS; Kim YJ; Kim J; Kim KG J Imaging Inform Med; 2024 Aug; 37(4):1674-1682. PubMed ID: 38378964 [TBL] [Abstract][Full Text] [Related]
20. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Ta RM; Hecht JL; Lin DI Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]